This story was first published in digitalhealth.net
Moderna to open UK vaccine research and manufacturing centre
Following an agreement between Moderna and the government, the pharmaceutical company is to build a state-of-the-art manufacturing and research and development centre in the UK.
The new mRNA Innovation and Technology Centre will develop mRNA vaccines for respiratory diseases including COVID-19. Construction is expected to begin this year, with the first mRNA vaccine due to be produced in the UK in 2025.
The centre will also have the ability produce vaccines targeting a range of other illnesses, such as flu and respiratory syncytial virus (RSV) and will be able to quickly scale up production in case of a health emergency.
Moderna supplied COVID-19 vaccines in the initial vaccine rollout in the UK, as well as in subsequent booster campaigns.
Stéphane Bancel, Chief Executive Officer of Moderna, said:
"The UK has established a world-class life sciences and research community. We are committed to global public health, and as we continue to expand internationally, we are pleased to bring local mRNA manufacturing to the UK."
The agreement with Moderna, which plans to deliver a large share of its clinical trials in the UK, was negotiated by the Vaccine Taskforce and supported by the Office for Life Sciences.
Latest News
16/02/2024 - 12:56
Hammersmith and Fulham Council has created a new alliance intended to clean dirty air and improve residents' health.
16/02/2024 - 10:44
Two million more GP appointments a month are being delivered for patients compared to the same month before the pandemic as part of the NHS primary care access recovery plan according to new NHS data.
15/02/2024 - 10:26
The Welsh Government has provided innovation funding of £380,000 to support two projects utilising technology in domiciliary care.
15/02/2024 - 10:13
The new Scottish health secretary has met with frontline staff at Queen Elizabeth University Hospital in Glasgow.
14/02/2024 - 10:27
The North East London NHS Foundation Trust (NELFT) has appointed three new Executive Directors to the Trust Board.
Product Features
UK Building Regulations highlight toxic gas and smoke from layers of paint built up over multiple redecorations as a major cause of permanent ill health or death in a building fire.
Their concern rose with discovery the flame retardant paints most widely used paint along escape routes have been ones which to this day counter-productively use emission of heavy toxic gas to smother flames which rapidly spread along walls if layers of paint delaminate in a fire.
Supplier Profiles
Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients
Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho
Latest Features
Sarah Greenslade, public affairs and communications officer at the British Parking Association looks at some of the problems and innovations in healthcare parking
It’s easy to assume that the comms team is there to handle press enquiries and the occasional social media storm – but the reality is that strategic communications can make a measurable impact across the entire organisation, from operational to financial, when done properly
